News
![3 Unstoppable Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/757538/two-people-with-ipad-and-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMHp0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3976f0ab1e5fe650966d197b4453873df4cb7039/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-people-with-ipad-and-laptop.jpg?locale=us)
3 Unstoppable Stocks to Buy Right Now
What are some unstoppable stocks to buy right now? Three Fool.com contributors think they've found three stocks that qualify -- and they're all in the healthcare sector. Here's why they picked
![AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?: https://g.foolcdn.com/editorial/images/757593/big-fish-eating-little-fish.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHp0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e01c1ac3cef4469a583fd7342610779797912f3d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/big-fish-eating-little-fish.jpg?locale=us)
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days.
![Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?: https://g.foolcdn.com/editorial/images/757762/scientists-high-five-smile.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUR0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a54aa343b4683e2163d9cb5f9cd52add5fdbb622/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-high-five-smile.jpg?locale=us)
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden
![Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?: https://g.foolcdn.com/editorial/images/757762/scientists-high-five-smile.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUR0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a54aa343b4683e2163d9cb5f9cd52add5fdbb622/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-high-five-smile.jpg?locale=us)
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden
![Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?: https://g.foolcdn.com/editorial/images/757762/scientists-high-five-smile.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUR0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a54aa343b4683e2163d9cb5f9cd52add5fdbb622/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-high-five-smile.jpg?locale=us)
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden
![2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond: https://g.foolcdn.com/editorial/images/756670/person-working-in-a-cannabis-dispensary.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1R0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--70fc4eaa675c411714a84185be2b810286dbc4aa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-working-in-a-cannabis-dispensary.jpg?locale=us)
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the
![2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond: https://g.foolcdn.com/editorial/images/756670/person-working-in-a-cannabis-dispensary.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1R0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--70fc4eaa675c411714a84185be2b810286dbc4aa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-working-in-a-cannabis-dispensary.jpg?locale=us)
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the
![2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond: https://g.foolcdn.com/editorial/images/756670/person-working-in-a-cannabis-dispensary.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1R0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--70fc4eaa675c411714a84185be2b810286dbc4aa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-working-in-a-cannabis-dispensary.jpg?locale=us)
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the
![3 Dividend Stocks Trading at 52-Week Lows: https://g.foolcdn.com/editorial/images/757729/gettyimages-1305501354.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0RzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--507edb15b88abc7856c35e55e4a93feb2b8aa063/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1305501354.jpg?locale=us)
3 Dividend Stocks Trading at 52-Week Lows
I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap.
In today's video I will look at three
![3 Dividend Stocks Trading at 52-Week Lows: https://g.foolcdn.com/editorial/images/757729/gettyimages-1305501354.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0RzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--507edb15b88abc7856c35e55e4a93feb2b8aa063/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1305501354.jpg?locale=us)
3 Dividend Stocks Trading at 52-Week Lows
I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap.
In today's video I will look at three
![2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years: https://g.foolcdn.com/editorial/images/757244/businesswoman-celebrating-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0hzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--68d4a85e2930bf3f997f9b9033fcdb2f8d9a2ffd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businesswoman-celebrating-1.jpg?locale=us)
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
While some stocks may not be attracting quite the same hype they were a few years ago, that doesn't mean the quality of their underlying businesses has evaporated. If your intention is to own great
![2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years: https://g.foolcdn.com/editorial/images/757244/businesswoman-celebrating-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0hzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--68d4a85e2930bf3f997f9b9033fcdb2f8d9a2ffd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businesswoman-celebrating-1.jpg?locale=us)
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
While some stocks may not be attracting quite the same hype they were a few years ago, that doesn't mean the quality of their underlying businesses has evaporated. If your intention is to own great
![2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years: https://g.foolcdn.com/editorial/images/757244/businesswoman-celebrating-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0hzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--68d4a85e2930bf3f997f9b9033fcdb2f8d9a2ffd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businesswoman-celebrating-1.jpg?locale=us)
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
While some stocks may not be attracting quite the same hype they were a few years ago, that doesn't mean the quality of their underlying businesses has evaporated. If your intention is to own great
![Is Pfizer Stock a Buy Now?: https://g.foolcdn.com/editorial/images/756932/businessman-with-a-chart-looking-at-his-computer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0hzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5759f679ffc52a61d932c6664738069c605edb0a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businessman-with-a-chart-looking-at-his-computer.jpg?locale=us)
Is Pfizer Stock a Buy Now?
Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. The top drugmaker can't seem to catch a break. Revenue from its COVID-19 products is down big, and
![Is Pfizer Stock a Buy Now?: https://g.foolcdn.com/editorial/images/756932/businessman-with-a-chart-looking-at-his-computer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0hzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5759f679ffc52a61d932c6664738069c605edb0a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businessman-with-a-chart-looking-at-his-computer.jpg?locale=us)
Is Pfizer Stock a Buy Now?
Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. The top drugmaker can't seem to catch a break. Revenue from its COVID-19 products is down big, and
![Could Sarepta Therapeutics Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/756930/gettyimages-1016186674.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2ZzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--768e2b757f5eddf0c7e2cf4a3b4a87b8aaff3ba4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1016186674.jpg?locale=us)
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
Sarepta Therapeutics (NASDAQ: SRPT) is a mid-cap stock that has the potential to be a big player in the gene therapy market -- at least, so the business and its investors hope. It has made for a
![3 Dividend Stocks You Can Safely Hold for Decades: https://g.foolcdn.com/editorial/images/757437/young-woman-smiling-hands-behind-head.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzdzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b291eabd97cb4e8f3285f29ba11476f5c17b4a72/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/young-woman-smiling-hands-behind-head.jpg?locale=us)
3 Dividend Stocks You Can Safely Hold for Decades
Remember Montgomery Ward, Lehman Brothers, and Pan Am? They were all well-known publicly traded companies that paid dividends. And they all went out of business.
Investors who bought those stocks
![Better Dividend Stock: AbbVie vs. Medical Properties Trust: https://g.foolcdn.com/editorial/images/757643/investor-at-home-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFBzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8a0e9eb8d610c4bef57cbeaf18961a4ea3e03bdb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-at-home-getty.jpg?locale=us)
Better Dividend Stock: AbbVie vs. Medical Properties Trust
Income-seeking investors have some interesting options to choose from in the healthcare sector right now. AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past
![Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?: https://g.foolcdn.com/editorial/images/757218/chemist-team-looking-beaker-of-green-chemical.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFBzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4d431282415dc0b1fbdbfd3911afb95369bdafb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chemist-team-looking-beaker-of-green-chemical.jpg?locale=us)
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not
![Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?: https://g.foolcdn.com/editorial/images/757218/chemist-team-looking-beaker-of-green-chemical.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFBzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4d431282415dc0b1fbdbfd3911afb95369bdafb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chemist-team-looking-beaker-of-green-chemical.jpg?locale=us)
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not
![2 Healthcare Stocks to Buy Hand Over Fist in December: https://g.foolcdn.com/editorial/images/757033/elderly-person-sitting-on-a-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHZzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9bbb14d42ec446eebcced5c9dcfdc747a20b6927/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/elderly-person-sitting-on-a-bed.jpg?locale=us)
2 Healthcare Stocks to Buy Hand Over Fist in December
As the year draws to a close, it's as good a time as any to review one's investments and consider adding more money into the stock market. The goal shouldn't be to take advantage of the January
![CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?: https://g.foolcdn.com/editorial/images/757216/chart-reflected-on-investor-glasses.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeURzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7ecd5cfae619a5a21b3d9fa5deb9316979343c8c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chart-reflected-on-investor-glasses.jpg?locale=us)
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
As reported by Fierce Biotech on Nov. 22, gene-therapy star CRISPR Therapeutics (NASDAQ: CRSP) laid off 10% of its employees shortly after reporting its Q3 earnings earlier in the month. Given that
![CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?: https://g.foolcdn.com/editorial/images/757216/chart-reflected-on-investor-glasses.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeURzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7ecd5cfae619a5a21b3d9fa5deb9316979343c8c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chart-reflected-on-investor-glasses.jpg?locale=us)
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
As reported by Fierce Biotech on Nov. 22, gene-therapy star CRISPR Therapeutics (NASDAQ: CRSP) laid off 10% of its employees shortly after reporting its Q3 earnings earlier in the month. Given that
![CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?: https://g.foolcdn.com/editorial/images/757216/chart-reflected-on-investor-glasses.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeURzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7ecd5cfae619a5a21b3d9fa5deb9316979343c8c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chart-reflected-on-investor-glasses.jpg?locale=us)
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
As reported by Fierce Biotech on Nov. 22, gene-therapy star CRISPR Therapeutics (NASDAQ: CRSP) laid off 10% of its employees shortly after reporting its Q3 earnings earlier in the month. Given that
![Why Viking Therapeutics Was Crushing It This Week: https://g.foolcdn.com/editorial/images/757638/person-in-a-lab-looking-through-a-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUhzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d3f1b0497e22bedfe3acf7f7a3e96e86328f1963/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-in-a-lab-looking-through-a-microscope.jpg?locale=us)
Why Viking Therapeutics Was Crushing It This Week
A multibillion-dollar deal in the healthcare industry helped lift the stock of a company, Viking Therapeutics (NASDAQ: VKTX), not directly involved in the transaction. The deal centered around a hot